CTLA4 and cancer: Vigorous research in the field of immunology has led to the development of a plethora of agents, also known as checkpoint inhibitors (i.e., anti-programmed death-1 (PD1)/PD-L1 and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)), which are able to interrupt the inhibitory conjunction of cancer and T-cells.